Скачать или смотреть Build for optionality—not every startup needs to be bought

In this episode highlight from our four-part series with KiraGen Bio CEO and co-founder Aaron Edwards, Aaron shares why he and his team are building lean, staying focused, and resisting the pressure to scale fast and exit.

Instead of chasing the “built to be bought” mindset, KiraGen is prioritizing scientific clarity, partnerships, and, chiefly, baking in some optionality—so they can grow on their own terms and choose a path forward that fits.

Find the full episode here: The Crazy Science That Might Cure Brain Cancer

Subscribe to our YouTube channel or listen on your favorite podcast platform for more content like this:
Youtube:    / @thebiotechstartupspodcast  
Apple: https://podcasts.apple.com/us/podcast...
Spotify: https://open.spotify.com/show/2PSL162...
Website: https://www.thebiotechstartupspodcast...

Guest—Aaron Edwards:
LinkedIn:   / aedwards02  
Company: https://www.kiragenbio.com/

Host—Jon Chee:
LinkedIn:   / excedr  
Company: https://www.excedr.com

Timestamps:
00:00 What’s next for Kiragen
01:00 Running lean and building with optionality
02:30 Why now is the best time to build

Keywords:
biotech startup, lean operations, CAR T-cell therapy, glioblastoma, IND filing, early-stage biotech, optionality, startup fundraising, venture capital, pre-seed round, seed funding, clinical trials, academic partnerships, capital efficiency, solid tumors, liquid malignancies, pharma collaboration, first-in-human data, startup growth strategy, cell therapy.

#biotech #startups #podcast